Cardiovascular related uses of il-1beta antibodies and binding fragments thereof

Abstract

Disclosed are methods for the reduction, prevention or treatment of cardiovascular events and/or cardiovascular diseases, including acute cardiovascular disease or chronic cardiovascular disease using anti-IL-1β binding molecules (e.g., IL-1β binding antibodies and fragments thereof). The present disclosure also relates to methods for prevention or treatment of cardiovascular events and/or cardiovascular diseases, including by reducing a cardiovascular event or disease.

1 . A method of reducing a cardiovascular event in a subject, comprising administering to said subject a therapeutically effective amount of an anti-IL-1β binding antibody or binding fragment thereof, wherein the subject is a subject with a history of a previous cardiovascular event or a history of at least one risk factor for cardiovascular disease, and wherein the cardiovascular event is myocardial infarction, stroke, cardiovascular death, congestive heart failure, cardiac arrest, acute coronary syndrome, angina, or a revascularization procedure. 
     
     
         2 - 17 . (canceled) 
     
     
         18 . A method of reducing mortality following a cardiovascular event in a subject, comprising administering to said subject a therapeutically effective amount of an anti-IL-1β binding antibody or binding fragment thereof. 
     
     
         19 - 38 . (canceled) 
     
     
         39 . A method of reducing a cardiovascular event in a subject with a history of at least one risk factor for cardiovascular disease, comprising administering to said subject a therapeutically effective amount of an anti-IL-1β binding antibody or binding fragment thereof, and wherein said risk factor is not Type 2 diabetes, obesity, hyperglycemia, dyslipidemia, hyperlipidemia, chronic renal failure, high blood glucose, chronic kidney disease, hypertension, atherosclerosis or metabolic syndrome. 
     
     
         40 - 57 . (canceled) 
     
     
         58 . A method of treating a cardiovascular event in a subject, wherein the cardiovascular event is myocardial infarction, stroke, congestive heart failure, acute coronary syndrome or angina, comprising administering to said subject a therapeutically effective amount of an anti-IL-1β binding antibody or binding fragment thereof and at least one other pharmaceutical composition comprising an active agent other than an IL-1β antibody or fragment. 
     
     
         59 . (canceled) 
     
     
         60 . A method for treating a cardiovascular event in a subject, wherein the cardiovascular event is myocardial infarction, stroke, congestive heart failure, acute coronary syndrome or angina, comprising administering to said subject a therapeutically effective amount of an anti-IL-1β binding antibody or binding fragment thereof and a revascularization procedure. 
     
     
         61 . (canceled) 
     
     
         62 . A method of reducing restenosis in a subject following a revascularization procedure, comprising administering to said subject a therapeutically effective amount of an anti-IL-1β binding antibody or binding fragment thereof. 
     
     
         63 - 64 . (canceled) 
     
     
         65 . A method of treating acute hypertension in a subject comprising administering to said subject a therapeutically effective amount of an anti-IL-1β binding antibody or binding fragment thereof and one or more antihypertensive agents. 
     
     
         66 - 107 . (canceled)